Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

Completed · Phase 3

Conditions studied: Hemophilia A

In brief

This study will examine the efficacy and safety of ReFacto AF in patients with severe and moderately severe hemophilia A undergoing elective major surgery when administered by either bolus injections (BI) or continuous infusion (CI).

Key facts

Study ID

NCT00243659

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

30

Starts

2006-04-01

Expected to finish

2008-06-01

Last updated by the study team

2011-06-03

Who can join

Age: 12 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Study site — La Jolla, California, United States
• Study site — Detroit, Michigan, United States
• Study site — Detroit, Michigan, United States
• Study site — Chapel Hill, North Carolina, United States
• Study site — Hershey, Pennsylvania, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Houston, Texas, United States
• Study site — Charlottesville, Virginia, United States
• Study site — Perth, Australia
• Study site — Vienna, Austria
• Study site — Budapest, Hungary
• Study site — Auckland, New Zealand
• Study site — Chirstchurch, New Zealand
• Study site — Warsaw, Poland
• Study site — Bucurest, Romania
• Study site — Malmö, Sweden
• Study site — Stockholm, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.